Clinical trials: Transfusions
Dysgerminoma
Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)
The aim is to determine the frequency of RBC transfusion in patients with metastatic "poor prognosis" germ cell tumor during high-dose chemotherapy (HD-VIP, level 6) with or without Darbepoetin alfa
- Trial name
- NCT00204633
- Testing
- Darbepoetin alfa
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- University Hospital Tuebingen
Hepatitis
A Controlled Prospective Study of Transfusion-Associated Hepatitis
This protocol represents a continuation of a series of prospective studies to define the incidence and etiology of transfusion-associated hepatitis (TAH) and to examine the impact on TAH of various modifications in the selection…
- Trial name
- NCT00004848
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Extracorporeal Membrane Oxygenation
The Effect of Prophylactic FFP Administration on ECMO Circuit Longevity
The purpose of this study is to assess the impact of scheduled fresh frozen plasma (FFP) administration on extracorporeal membrane oxygenation (ECMO) pump longevity in critically ill pediatric and neonatal patients.
- Trial name
- NCT01903863
- Testing
- Fresh frozen plasma
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Duke University
Neonatal Thrombocytopenia, Intraventricular Hemorrhage
Monitoring Outcome in Neonatal Thrombocytopenia
Rationale: Approximately 10% of neonates admitted to neonatal intensive care units develop a major hemorrhage. In an attempt to avert this severe complication various preventive measures have been implemented.
- Conditions
- Neonatal Thrombocytopenia, Intraventricular Hemorrhage, Platelet Transfusion
- Trial name
- MONET (NCT03110887)
- Volunteers
- 700 people
- Sponsor
- Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
Bleeding in Liver Transplantation
Plasma Transfusion in Liver Transplantation
The aim of the study is to compare the clinical efficacy of three types of plasma secured on the viral level either by quarantine or by chemical treatment in patients undergoing liver transplantation.
- Trial name
- NCT00235183
- Testing
- plasma
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Etablissement Français du Sang
Osteoarthritis
Blood Management in Orthopedic Surgery
Aim: to investigate whether the use of several transfusion alternatives (erythropoietin, the cell-saver or postoperative drainage and reinfusion systems) in patients undergoing elective total knee or hip replacement surgery can…
- Trial name
- TOMaat (NCT00998088)
- Testing
- erythropoietin and cell saver, erythropoietin, OrthoPAT
- Where
- 4 sites in Netherlands
- Volunteers
- 2,598 people
- Sponsor
- Sanquin Research & Blood Bank Divisions
Myelodysplastic Syndromes
The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality
The purpose of this study is to evaluate the efficacy of lenalidomide treatments to achieve haematopoietic improvement in subjects with low- or intermediate-1 risk International Prognostic Scoring System1 (IPSS) myelodysplastic…
- Trial name
- NCT00874978
- Testing
- lenalidomide
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- King's College Hospital NHS Trust
Traumatic Brain Injury
Age of Blood in Brain Injury
Donated red blood cells vary in how old they are, that is, how long they have been stored since being collected from donors. Blood that has been donated is stored for a maximum of 42 days, after this time it is expired.
- Trial name
- NCT00141674
- Testing
- Blood Transfusion
- Where
- Canada
- Volunteers
- 60 people
- Sponsor
- University of British Columbia
Erythrocyte Transfusion
Rejuvenated RBC and VO2 Max in Healthy Subjects
To compare the physiologic benefits of rejuvenated RBCs (rejRBCs) to standards RBCs (PRBCs), we will emulate critical conditions by safely maximizing stress on the cardiovascular system, in an elective, feasible volunteer study.
- Trial name
- NCT03089047
- Testing
- Transfusion of rejuvenated and washed autolgous RBCs, Transfusion of washed autolgous RBCs
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Duke University
Lymphoproliferative Disorders
Transfusion-related EBV Infection Among Allogeneic Stem Cell Transplant Pediatric Recipients
In many countries, numerous steps are taken to minimize the risk of infection from transfused blood products. Typically, blood banking organisations will screen for an array of infectious pathogens as part of their quality…
- Trial name
- TREASuRE (NCT02505789)
- Testing
- Determining the source of EBV in severe EBV infections
- Where
- 3 sites in Canada
- Volunteers
- 324 people
- Sponsor
- St. Justine's Hospital
Knee Osteoarthritis, Blood Loss
Use of Tranexamic Acid in the Total Knee Arthroplasty.
Tranexamic acid is a medication used to treat or prevent excessive blood loss during surgery. Previous studies have shown tranexamic acid (TXA) reduces blood loss and post-operative blood transfusion rate without significant…
- Conditions
- Knee Osteoarthritis, Blood Loss, Blood Transfusion
- Trial name
- NCT05919615
- Testing
- Tranexamic Acid 100 MG/ML, Normal saline
- Where
- Syria
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Damascus University
Diabetic Wounds, Platelet Rich Plasma
Allogeneic vs Autologous PRP for Diabetic Wounds in Renal Dysfunction: a Randomized Controlled Trial
Diabetic wounds are difficult to heal. Autologous platelets in diabetic patients with renal insufficiency have poor function. Allogeneic platelet plasma has a promising application prospect.
- Conditions
- Diabetic Wounds, Platelet Rich Plasma, Allogeneic Blood Transfusions, Renal Dysfunction
- Trial name
- NCT07020559
- Testing
- allogeneic platelet plasma, autologous platelet plasma
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Peking University Third Hospital
Renal Failure
Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation
Safety during transfusions is a major issue in medical economics. Despite drastic quality control measures, transfusion is still a source of short, mid and long-term morbi-mortality.
- Trial name
- TRANSNEPHRON (NCT02763410)
- Testing
- PRBC transfusion
- Where
- France
- Volunteers
- 199 people
- Sponsor
- Nantes University Hospital
Myelodysplastic Syndromes
Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.
The goal of the present study is to assess, through a randomized phase II trial, the efficacy and safety of Lenalidomide with or without Epoetin beta in transfusion-dependent, ESA-resistant, IPSS low and intermediate-1 risk MDS…
- Trial name
- NCT01718379
- Testing
- Lenalidomide, Epoetin beta
- Where
- 48 sites in France, Monaco
- Volunteers
- 132 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Myelodysplastic Syndromes, Anemia
A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion
The purpose of this study is to demonstrate that Epoetin alfa treatment reduces red blood cell transfusions in anemic patients with myelodysplastic syndromes (MDS).
- Trial name
- NCT00695396
- Testing
- Epoetin alfa
- Volunteers
- 25 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Gastric Cancer, Pancreatic Cancer
Study of Tranexamic Acid for Reducing Blood Requirement in Patients Undergoing Major Gastro-intestinal Surgery
Primary objective of the study is to compare requirement of blood transfusion and mortality in patients receiving Tranexamic acid (Cyklokapron®) and those not receiving it.
- Conditions
- Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colon Cancer
- Trial name
- TMGS (NCT01655641)
- Testing
- Tranexamic acid, Standard of care
- Where
- Nepal
- Volunteers
- 118 people
- Sponsor
- Tribhuvan University Teaching Hospital, Institute Of Medicine.
Iron Overload
Retrospective Evaluation of Adult and Pediatric Transfusion-dependent Patients Treated With Deferasirox Therapy
Iron overload is a leading cause of morbidity and mortality in transfusion-dependent patients. Deferasirox is the most promising iron chelator agent in several clinical scenarios.
- Trial name
- NCT01874405
- Volunteers
- 80 people
- Sponsor
- University of Campania Luigi Vanvitelli
Heart Disease
Prediction of Bleeding and Transfusion Outcomes and Assessment of Perioperative Platelet Reactivity in Cardiac Surgery
Excessive bleeding after cardiopulmonary bypass (CPB) operations remains to be a persistent problem. Antiplatelet therapy (APT) is an integral component of perioperative management in patients undergoing cardiac surgery.
- Trial name
- NCT02277379
- Where
- Croatia
- Volunteers
- 113 people
- Sponsor
- University of Zagreb
Post Operative Hemorrhage, Transfusion Related Complication
Monitoring Noninvasively for Infusion and Transfusion Optimization
This is a multicenter, cluster randomized controlled trial to assess the effects of an optimized intraoperative fluid and blood management strategy on postoperative complications.
- Conditions
- Post Operative Hemorrhage, Transfusion Related Complication, Blood Transfusion Associated Adverse Reactions, Hypovolemia
- Trial name
- NCT04388722
- Testing
- Pulse CO-Oximeter Sensor
- Sponsor
- Masimo Corporation
Anemia
Mortality After Transfusion of Ever-pregnant Donor Red Blood Cells
The MATER study is an observational cohort study on first ever transfusion recipients in six hospitals in the Netherlands, with information collected on both donor and patient characteristics.
- Trial name
- MATER (NCT06176105)
- Where
- Netherlands
- Volunteers
- 101,000 people, healthy volunteers welcome
- Sponsor
- Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.